Cargando…
Pharmacologic Activation of the G Protein–Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma
BACKGROUND & AIMS: Female sex is associated with lower incidence and improved clinical outcomes for most cancer types including pancreatic ductal adenocarcinoma (PDAC). The mechanistic basis for this sex difference is unknown. We hypothesized that estrogen signaling may be responsible, despite t...
Autores principales: | Natale, Christopher A., Li, Jinyang, Pitarresi, Jason R., Norgard, Robert J., Dentchev, Tzvete, Capell, Brian C., Seykora, John T., Stanger, Ben Z., Ridky, Todd W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578406/ https://www.ncbi.nlm.nih.gov/pubmed/32376419 http://dx.doi.org/10.1016/j.jcmgh.2020.04.016 |
Ejemplares similares
-
Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018) -
Isoprostane F(2α)-VI, a new marker of oxidative stress, increases following light damage to the mouse retina
por: Dentchev, Tzvete, et al.
Publicado: (2007) -
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022) -
Gα15 in early onset of pancreatic ductal adenocarcinoma
por: Innamorati, Giulio, et al.
Publicado: (2021) -
Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
por: Weng, Ningna, et al.
Publicado: (2022)